文献速递主动脉疾病

一期杂交全主动脉弓及降胸主动脉修复术安全可行且并发症较少

One-Stage Hybrid Total Aortic Arch and Descending Thoracic Aortic Repair is a Safe and Secure Procedure With Less Postoperative Complications for Extended Aortic Arch Aneurysms.
PubMed 文献 · J Endovasc Ther · 2021-09-28

本研究回顾性比较了56例接受杂交主动脉弓修复术(HAR)的广泛主动脉弓疾病患者与75例接受全弓置换术(TAR)的局限弓部疾病患者,中位随访36个月。HAR组未观察到手术死亡、院内死亡及永久性神经功能缺损,截瘫率1.8%。在非破裂粥样硬化性主动脉弓动脉瘤患者中,II-1型HAR术后呼吸支持时间短于TAR(p<0.01),但Cox回归分析未显示两种术式在6年无全因死亡、无手术相关并发症及无再干预率上存在统计学差异。

要点

  • HAR尤其II-1型可用于广泛主动脉弓疾病,围术期死亡及永久性神经缺损为零。
  • II-1型HAR术后呼吸支持时间短于TAR,但TEVAR相关并发症影响远期无并发症生存。
  • 两种术式6年无全因死亡、无手术相关并发症及无再干预率无统计学差异。

核心结论

  • HAR尤其II-1型可治疗广泛主动脉弓疾病,生存结局可接受。

研究设计与样本

  • 回顾性单中心研究,2007至2019年56例HAR治疗广泛主动脉弓疾病,75例TAR治疗局限弓部疾病。
  • HAR为1期完成主动脉替换、全部弓部血管重建及体外循环停机后zone 0至降主动脉的TEVAR。
  • II-1型HAR最常采用(40/56例),其结局与TAR用Cox回归分析比较。

主要发现

  • HAR组未观察到手术死亡、院内死亡及术后永久性神经功能缺损。
  • HAR组截瘫率为1.8%,TEVAR相关并发症发生于3例患者。
  • 非破裂粥样硬化性主动脉弓动脉瘤患者中,II-1型HAR术后呼吸支持时间短于TAR(p<0.01)。
  • II-1型HAR 6年无全因死亡率为83.1%,TAR为74.7%,数值上前者较高但无统计学差异。
  • II-1型HAR 6年无手术相关并发症率为90.3%,TAR为96.9%,数值上前者较低但无统计学差异。

关键数值与推荐

  • II-1型HAR 6年无再干预至降胸主动脉率为100%,TAR为83.7%,数值上前者较好但Cox回归无统计学差异。
  • Cox回归分析未显示II-1型HAR与TAR在结局上存在统计学差异。

临床怎么用

  • 对广泛主动脉弓疾病可考虑一期HAR尤其II-1型,围术期安全性可接受。
  • 需关注TEVAR相关并发症对远期无并发症生存的影响。

局限性

  • 原文未报告

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Hybrid aortic arch repair (HAR) has been implemented for extended aortic arch and descending thoracic aortic disease since 2012 in our institution. This study aimed to estimate the early and mid-term efficacy and safety of HAR. MATERIALS AND METHODS: From 2007 to 2019, 56 patients underwent HAR for extended aortic arch disease, and 75 patients underwent total arch replacement (TAR) for arch-limited disease. HAR comprises 3 procedures: replacement of the aorta, reconstruction of all arch vessels, and thoracic endovascular aortic repair (TEVAR) from zone 0 to the descending aorta after cardiopulmonary bypass is off in 1 stage. The type II-1 HAR procedure, in which the ascending aorta and aortic arch distal to the brachiocephalic artery are replaced, was the most frequently selected procedure (40/56 patients). The outcomes of the type II-1 HAR procedure were compared with those of TAR using the Cox regression analysis. RESULTS: The median follow-up period was 36 months. In HAR, the operative mortality, in-hospital mortality, and postoperative permanent neurological deficits were not observed. The paraplegia rate was 1.8%. TEVAR-related complications occurred in 3 patients. Among the patients with non-ruptured atherosclerotic aortic arch aneurysm (31 type II-1 HAR patients and 36 TAR patients, the postoperative respiratory support time in those who underwent type II-1 HAR was quicker than in those who underwent TAR (p<0.01). The rate of 6 year freedom from all-cause death in type II-1 HAR (83.1%) was numerically higher than that in TAR (74.7%), and the rate of 6 year freedom from surgery-related complications in type II-1 HAR (90.3%) was numerically lower than that in TAR (96.9%) due to the occurrence of TEVAR-related complications, and the rate of 6 year freedom from reintervention to the descending thoracic aorta in type II-1 HAR (100%) seemed to be better than that in TAR (83.7%). However, Cox regression analysis did not reveal any statistical difference between the 2 procedures. CONCLUSIONS: HAR, especially the type II-1 procedure, can treat extended aortic arch disease with acceptable survival outcomes. The development of TEVAR technology will further improve the outcomes of HAR in the future.

来源:J Endovasc Ther,查看原文。版权归原作者所有。

引用

  1. Mizuno T, Hachimaru T, Fujiwara T, et al. One-Stage Hybrid Total Aortic Arch and Descending Thoracic Aortic Repair is a Safe and Secure Procedure With Less Postoperative Complications for Extended Aortic Arch Aneurysms. J Endovasc Ther. 2021. PMID: 34581224. doi:10.1177/15266028211047954

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。